ArticleAnnals of hematology2024

A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis.

Ghaith Abu-Zeinah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.